In a phase IIa trial in patients with atopic dermatitis, IL-22 levels were correlated with disease severity measures at baseline: Eczema Area and Severity Index (EASI; p<0.0001) and SCORing Atopic Dermatitis (SCORAD; p=0.001) (25). Here, IL22 is linked to Eczematoid dermatitis.